24 filings
8-K
ADXS
Ayala Pharmaceuticals, Inc.
20 Dec 19
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
4:31pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
25 Oct 19
Advaxis Announces Business and Pipeline Update
12:00am
8-K
ADXS
Ayala Pharmaceuticals, Inc.
4 Oct 19
Other Events
4:31pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
13 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
9 Sep 19
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
4:30pm
8-K
0tlzi0i ua
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
svgz9nvj6j1it60j3
22 Aug 19
Advaxis, Inc. Issues Letter to Shareholders
4:15pm
8-K
m0qkav7fh0uyourp0
31 Jul 19
Material Modifications to Rights of Security Holders
4:15pm
8-K
16qkvp8
25 Jul 19
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
5:19pm
8-K
z1jldonnzosei1q
15 Jul 19
Other Events
9:38am
8-K
gfw96t
27 Jun 19
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of its Phase 3 AIM2CERV Study
4:30pm
8-K
mua8sw0dr0vqy5 fg8
10 Jun 19
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
5:28pm
8-K
cmkul
15 May 19
Other Events
10:00am
8-K
rroeyvq rjd
13 May 19
Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
4:30pm
8-K
9uuk 9by6d9xdy2ae0l
15 Apr 19
Other Events
12:01pm
8-K
5folfj54v
5 Apr 19
Entry into a Material Definitive Agreement
4:05pm
8-K
1xycbwft5rn10dw0dg
29 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
l2c0x twvi
15 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
9jg37b
14 Mar 19
Entry into a Material Definitive Agreement
9:30am
8-K
dfrxk9
12 Mar 19
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
4:30pm